Merit Medical Systems, Inc. (NASDAQ:MMSI) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 51.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,555 shares of the medical instruments supplier’s stock after selling 4,924 shares during the period. SG Americas Securities LLC’s holdings in Merit Medical Systems were worth $450,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Opal Wealth Advisors LLC acquired a new stake in shares of Merit Medical Systems during the second quarter worth about $29,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Merit Medical Systems during the first quarter worth about $44,000. Headlands Technologies LLC acquired a new stake in shares of Merit Medical Systems during the first quarter worth about $50,000. GAMMA Investing LLC boosted its stake in shares of Merit Medical Systems by 142.3% during the second quarter. GAMMA Investing LLC now owns 831 shares of the medical instruments supplier’s stock worth $71,000 after buying an additional 488 shares during the period. Finally, National Bank of Canada FI acquired a new stake in shares of Merit Medical Systems during the second quarter worth about $77,000. Institutional investors and hedge funds own 99.66% of the company’s stock.

Merit Medical Systems Trading Down 0.4 %

Shares of Merit Medical Systems stock opened at $95.25 on Thursday. Merit Medical Systems, Inc. has a 12-month low of $63.13 and a 12-month high of $101.60. The company has a current ratio of 6.24, a quick ratio of 4.64 and a debt-to-equity ratio of 0.62. The stock has a market cap of $5.53 billion, a PE ratio of 54.74, a price-to-earnings-growth ratio of 2.41 and a beta of 0.87. The company has a 50-day moving average of $95.40 and a two-hundred day moving average of $86.03.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.04. Merit Medical Systems had a net margin of 9.02% and a return on equity of 15.29%. The company had revenue of $338.00 million during the quarter, compared to analysts’ expectations of $334.94 million. On average, research analysts anticipate that Merit Medical Systems, Inc. will post 3.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MMSI. Piper Sandler reiterated an “overweight” rating and set a $110.00 target price (up previously from $100.00) on shares of Merit Medical Systems in a research note on Monday, September 9th. Needham & Company LLC reissued a “buy” rating and set a $105.00 price target on shares of Merit Medical Systems in a report on Monday, September 16th. Robert W. Baird initiated coverage on shares of Merit Medical Systems in a report on Friday, June 28th. They set an “outperform” rating and a $96.00 price target for the company. Barrington Research increased their price target on shares of Merit Medical Systems from $100.00 to $114.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Finally, Canaccord Genuity Group increased their price target on shares of Merit Medical Systems from $102.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.82.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.